Local Anesthesia Drugs Market Size, Share & Trends Analysis Report By Product (Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine), By Application, And Segment Forecasts, 2018 - 2025

Report Overview

The global local anesthesia drugs market size to be valued at USD 6.45 billion by 2025 and is expected to grow at a compound annual growth rate (CAGR) of 3.7% during the forecast period. There has been an increase in the number of surgical procedures performed across the globe, including dental procedures, cosmetic surgeries, and plastic surgeries. This is a major factor driving the market for local anesthetics. A key trend observed in the market is a significant rise in demand for post-operative pain relief options, on the heels of an increasing number of surgical procedures. This trend is likely to continue throughout the forecast period, positively influencing the demand for local anesthesia drugs. An approximate 65.0% of the total surgical procedures performed need postoperative pain management.

Growth in the number of surgeries performed can be attributed to the aging population, a demographic group that is more prone to chronic diseases such as cardiovascular disorders, respiratory ailments, cancer, neurological disorders, and other gastro, orthopedic, and spinal problems. Advancements in drug delivery technologies are also expected to contribute to the demand for local anesthetics in surgical procedures. For instance, DepoFoam technology uses a new method to deliver bupivacaine and is very efficient in the management of post-operative pain.

The growth of the market for local anesthesia drugs is also fueled by the introduction of new and effective drugs such as articaine, levobupivacaine, and ropivacaine. This growth is supplemented by increasing healthcare expenditure in developing countries such as India, China, and Brazil, where the number of surgeries performed has been on a steady rise.

Local Anesthesia Drugs Market Trends

Various factors such as the rising number of surgeries, new anesthetic medication approvals, and the expanded use of local anesthetics in post-operative pain are driving the expansion for local anesthesia pharmaceuticals market. Moreover,the anesthetic medications are primarily used during surgical operations. As a result, the local anesthesia market is expected to grow substantially owing to its significance during crucial surgeries

The demand for local anesthesia in the industry is fueled by several factors. Within the projected period, the global-local anesthesia pharmaceuticals market is expected to grow due to an increase in the surgical cases and advancements in drug delivery, such as computer-based local anesthetic delivery and vibrotactile devices.

However, the market is projected to be constrained by the negative effects of these treatments and a stringent regulatory framework. Some significant medication side effects, such as CNS toxicity, respiratory depression and cardiovascular toxicity are among the significant reasons holding back the worldwide local anesthetic pharmaceuticals market from reaching its full potential.

Product Insights

On the basis of product, the local anesthesia drugs market has been segmented into bupivacaine, ropivacaine, lidocaine, chloroprocaine, prilocaine, benzocaine, and other local anesthetics. The lidocaine drug dominated the market in 2016 owing to its extensive use as a topical and injectable anesthetic. The entry of newer drugs such as articaine and bupivacaine will, however, threaten to challenge the market share of this drug over the forecast period.

Bupivacaine is expected to witness the fastest growth through 2025 due to a significant number of clinical trials conducted on the drug as of 2016. The growth is also attributed to its extensive use in postoperative pain management. Drugs such as ropivacaine and articaine are also expected to witness promising growth over the forecast period.

Application Insights

In terms of application, the market for local anesthesia drugs has been bifurcated into injectable and surface anesthetics. By way of revenue, the injectable anesthetics segment dominated the market and this trend is likely to continue during the forecast period. This is primarily attributed to the extensive usage of injectable anesthetics in different surgical procedures. Surface anesthetics, on the other hand, are anticipated to witness the fastest growth over the forecast period. Advancements in drug delivery systems are expected to be the key driving factor for this segment.

Regional Insights

North America held the largest share in the market owing to a significant number of surgical procedures performed in the U.S. The country accounts for more than 25.0% of surgical procedures performed across the globe. High per capita income, improved access to healthcare, an increase in the prevalence of chronic diseases, and rising geriatric population are driving the market for local anesthesia drugs in this region.

Europe held the second-largest share as of 2016 and is expected to witness decent growth during the forecast period. The growth is attributed to the increasing volume of dental and cosmetic surgeries, advancements in surgical procedures, and growing use of local anesthetics in post-operative pain management.

The Asia Pacific and Latin American markets are expected to exhibit lucrative growth over the forecast period owing to expanding geriatric population, which is anticipated to drive the number of surgical procedures performed in the region. The decline in opioid use in the region is also expected to contribute to market growth.

Key Companies & Market Share Insights

Some of the key players in the market for local anesthesia drugs are Aspen Pharmacare; Fresenius Kabi; Novartis, Inc.; Sagent Pharmaceutical; Pacira Pharmaceutical; Mylan; and Teva Pharmaceuticals. There are numerous regional and local generic players in the market, which makes the market increasingly competitive. GlaxoSmithKline and AstraZeneca recently divested their anesthesia portfolio to Aspen Pharmacare, making Aspen one of the largest suppliers of anesthesia drugs across the globe.

Recent Developments

• In March, 2021, Pacira BioSciences Inc.'s introduced supplemental new drug application (sNDA) for the augmented use of Exparel (Bupivacaine Liposome Injectable Suspension) in pediatric patients that was approved by the U.S. Food and Drug Administration (FDA).

• In December 2021, Hikma Pharmaceuticals PLC (Hikma) introduced Bupivacaine HCl Injection USP through its U.S. subsidiary Hikma Pharmaceuticals USA Inc. In 10 ml and 30 ml doses.

Local Anesthesia Drugs Market Report Scope

Global Local Anesthesia Drugs Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the local anesthesia drugs market report on the basis of product, application, and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Bupivacaine

  • Ropivacaine

  • Lidocaine

  • Chloroprocaine

  • Prilocaine

  • Benzocaine

  • Other local anesthetics

• Application Outlook (Revenue, USD Million, 2014 - 2025)

  • Injectable

  • Surface Anesthetic

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa